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ABSTRACT
We previously identified the chemokine receptor CCR4 as part of the molecular 
signature of melanoma brain metastasis. The aim of this study was to determine 
the functional significance of CCR4 in melanoma brain metastasis. We show that 
CCR4 is more highly expressed by brain metastasizing melanoma cells than by local 
cutaneous cells from the same melanoma. Moreover, we found that the expression 
of CCR4 is significantly higher in paired clinical specimens of melanoma metastases 
than in samples of primary tumors from the same patients. Notably, the expression 
of the CCR4 ligands, Ccl22 and Ccl17 is upregulated at the earliest stages of brain 
metastasis, and precedes the infiltration of melanoma cells to the brain. In-vitro, CCL17 
induced migration and transendothelial migration of melanoma cells. Functionally, 
human melanoma cells over-expressing CCR4 were more tumorigenic and produced 
a higher load of spontaneous brain micrometastasis than control cells. Blocking 
CCR4 with a small molecule CCR4 antagonist in-vivo, reduced the tumorigenicity and 
micrometastasis formation of melanoma cells. Taken together, these findings implicate 
CCR4 as a driver of melanoma brain metastasis.
INTRODUCTION
It is well established that interactions between tumor 
cells with non-tumor cells in the tumor microenvironment 
drive tumor progression towards metastasis [1–3]. These 
tumor-microenvironment interactions are bidirectional 
and each interaction partner regulates and shapes the 
phenotype of the other partner.
Determinants of metastasis are cells or molecules 
whose activity is required for the targeted migration of 
metastasizing tumor cells to the secondary target organ 
and for their survival and propagation within this organ. 
Both intrinsic tumor factors as well as microenvironmental 
factors could function as determinants of metastasis and 
both are target candidates for novel therapies. 
To identify and characterize determinants of 
metastasis we developed human to mouse xenograft 
models comprising non-metastatic and metastatic 
variants originating in the same human neuroblastoma 
or melanoma [4–6] tumors. Since these variants have 
identical genetic backgrounds, transcriptomic, proteomic, 
genomic and epigenomic differences between non-
metastatic and metastatic variants can be attributed 
to differences between their metastatic phenotypes. 
Employing melanoma variants, we established a molecular 
signature of melanoma brain metastasis (MBM) including 
among others, the chemokine receptor CCR4 [5, 6] and 
the tight junction protein Claudin-1 [7]. 
The chemokine (C-C) motif receptor 4 (CCR4) and 
its ligands CCL17 and CCL22 are regulators of immune 
responses especially those mediated by regulatory T 
cells (Tregs) and TH2 cells [8, 9]. In ovarian cancer 
CCR4+Tregs migrate towards CCL22 produced by tumor 
cells or by the tumor microenvironment, thereby creating 
favorable conditions for tumor growth. High levels of 
Treg cells were detected in a variety of solid tumors such 
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as breast, colorectal, esophageal, gastric, lung and liver 
cancer and melanoma [10]. CCR4 is associated with high 
tumor recurrence and poor prognosis of gastric cancer 
patients [11].
Cutaneous and brain-metastasizing melanoma 
variants stimulated with the CCR4 ligand CCL22, showed 
a differential AKT phosphorylation pattern [6]. The 
expression of this chemokine receptor was regulated by the 
brain microenvironment, as brain derived-soluble factors 
upregulated CCR4 expression in melanoma cells [12]. 
We also demonstrated that highly malignant vemurafenib 
(BRAFmt inhibitor)-resistant human melanoma cells 
expressed high levels of CCR4. CCL17 and CCL22 
expression was upregulated in several organs including 
lung, liver and brain of the tumor-bearing nude mice 
harboring these highly malignant tumors [13].
These findings led us to investigate the functional 
significance of CCR4 in melanoma brain metastasis both 
at the clinical setting as well as in experimental models.
RESULTS
CCR4 is upregulated in brain-tropic melanoma 
cells 
Our previous results have indicated that the 
chemokine receptor CCR4 is significantly upregulated in 
brain-metastasizing melanoma cells [6]. To expand this 
observation, we evaluated the expression of CCR4 in a 
panel of three patient-derived cell lines of MBM (YDFR, 
UCLA-SO-M12, and UCLA-SO-M16). Flow cytometry 
analysis revealed that brain metastasizing human 
melanoma cell variants (YDFR.CB4, M12.CB3 and M16.
CB2 - referred here after as HBMMC) [5], expressed 
higher levels of CCR4 than cells from the corresponding 
local YDFR.C, M12.C and M16.C variants (Figure 1A). 
We next asked whether the difference in CCR4 
expression between local and HBMMC is also manifested 
under three-dimensional (3D) growth conditions, which 
represent more closely the in-vivo reality [14–16]. We 
found that CCR4 expression is significantly higher 
(p < 0.05) on local melanoma variants propagating in 
3D culture than on the same cells growing under 2D 
conditions (Figure 1B), suggesting that the extracellular 
matrix in 3D cultures has a regulatory effect on the 
expression of CCR4.
As mentioned above, the expression of CCR4 is 
regulated by the brain microenvironment [12]. In an 
effort to create an in-vitro system mimicking the brain 
microenvironment, we added soluble factors derived 
from microglia cells, an important constituent of the brain 
microenvironment, to cutaneous and HBMMC grown 
in 3D culture. The results (Figure 1B) demonstrated 
that microglia-derived soluble factors upregulated the 
expression of CCR4 by melanoma cells.
The next set of experiments was aimed to establish 
whether CCR4 is expressed by brain-metastasizing 
melanoma cells in-vivo. The results presented in Figure 
1C and 1D show that CCR4 is highly expressed by 
human melanoma cells in brain metastatic lesions of the 
xenografted nude mice. 
Taken together, these results show that the brain 
microenvironment is involved in the regulation of CCR4 
expression by MBM. 
CCR4 expression is highly upregulated in 
clinical samples of melanoma brain metastasis 
The clinical relevance of the above results was 
validated by examining the expression of CCR4 in paired 
samples of primary melanoma (PRM), lymph node 
metastasis (LNM), and MBM derived from melanoma 
patients. This cohort included 12 patients. Paired triplets 
(PRM; LNM; MBM) were derived from 8 patients, paired 
duplets (PRM-LNM) or (LNM-MBM) were derived from 
3 patients. A single MBM was also analyzed. IHC staining 
indicated that metastatic melanomas (LNM and MBM) 
exhibited significantly (p < 0.05) higher expression of 
CCR4 than paired PRMs (Figure 2A–2B).
CCR4 ligands are expressed and secreted by 
human brain stromal cells 
We previously demonstrated that the CCR4 ligands 
CCL17 and CCL22 are expressed in the brain [6]. Based 
on these results and those described above, (Figure 1), 
we hypothesized that the targeted migration of CCR4-
expressing melanoma cells is mediated by an interaction 
between CCR4 expressed by melanoma cells and CCR4 
ligands expressed in the brain. In order to identify the 
cellular source of the CCR4 ligands in the brain, we 
performed qRT-PCR assays using cultures of human 
astrocytes, microglia and brain endothelial cells and 
found that all 3 types of brain cells express CCL17and 
CCL22. It should be noted that these cells require stress 
conditions (e.g. starvation medium) or activation signals 
(e.g. exposure to melanoma-derived supernatants – see 
below) to express the CCR4 ligands. 
We next utilized a human chemokine array to 
evaluate secretion of the ligands from astrocytes, 
microglia and brain endothelial cells. These cells were 
incubated in starvation medium containing 0.5% FCS for 
24 h. Conditioned medium collected from these cells was 
analyzed for the relative expression of the CCR4 ligands 
CCL17 and CCL22. We found that all 3 types of brain 
cells secreted CCL17 (Figure 3A) and CCL22 (Figure 3B, 
suggesting that these cells are a physiological source of 
the CCR4 ligands. 
As shown earlier (Figure 1B) microglial cells 
interacted with melanoma cells and altered the expression 
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of CCR4 in these cells. We asked whether these 
interactions are reciprocal, and analyzed if melanoma cells 
are capable of altering the secretion of CCR4 ligands from 
microglial cells. Using a human chemokine array (see 
Figure 3A–3B), we measured the secretion level of CCL17 
(Figure 3C) and CCL22 (Figure 3D) from 3D cultures of 
microglial cells cultured with or without melanoma cells. 
In line with our hypothesis, microglial cells co-cultured 
with melanoma cells secreted higher levels of both CCL17 
and CCL22 (Figure 3C and 3D) than microglial cells 
grown alone.
In order to test if the bearing of a subcutaneous 
melanoma tumor and/or the presence of melanoma 
micrometastasis in the brain leads to alterations in the 
expression of CCR4 ligands in this organ, we measured 
the expression of the CCR4 ligands in the brain at different 
time points following a subcutaneous inoculation of 
HBMMC to nude mice. The expression of CCR4 ligands 
in the brain was determined 3, 5 and 10 wks following 
tumor cell inoculation. The results indicated that Ccl17 
(but not Ccl22) expression was significantly upregulated 
10 wks following tumor cell inoculation (Figure 3E–3F 
respectively). At this time point, no micrometastases were 
detected in the brain. This shows that the bearing of local, 
cutaneous melanoma tumors regulates the levels of CCL17 
in the brain by a mechanism operating long distance. We 
suggest that the up-regulated levels of CCL17 in the brain 
could chemo-attract CCR4-expressing melanoma cells 
towards this organ. 
The CCR4-CCL17 axis promotes melanoma cell 
viability and facilitates their in-vitro migration 
We next asked if the CCR4-CCR4 ligand axis 
is involved in the viability and migratory activity of 
melanoma cells and in particular in their trans-endothelial 
migration through brain endothelial cells. To this end, we 
generated a CCR4-overexpressing cutaneous variant of the 
YDFR melanoma by viral transduction of CCR4 DNA. 
Control cells were transduced with scrambled CCR4 
DNA (CON). These infections yielded CCR4hi and CON 
variants, respectively (Figure 4A–4B).
To assess the effect of CCR4 on melanoma cell 
viability we utilized an XTT-based assay to determine the 
viability of CCR4hi and CON cells in culture. The results 
(Figure 4C) show that the viability of CCR4hi cells was 
significantly higher than that of CON cells showing that 
CCR4 stimulates growth of melanoma cells (Figure 4C).
Figure 1: CCR4 is upregulated in brain-tropic melanoma cells. (A) FACS analysis for CCR4 expression by local melanoma 
variants compared to brain metastasizing melanoma variants (HBMMC) from 3 different melanomas (YDFR, M-12, M-16). Graphs show 
the average % positive cells in three independent experiments, *p < 0.05. (B) FACS analysis for CCR4 expression of local and of brain 
metastasizing melanoma cells (HBMMC). Melanoma cells grown in 3D cultures (3D) express higher levels of CCR4 than cells grown 
in 2D cultures (2D). Addition of microglia-derived soluble factors to melanoma cells grown in 3D cultures (3D+MG) upregulated the 
expression of CCR4 even more. Graphs show the average % positive cells in three independent experiments, *p < 0.05. (C–D) Brain 
sections of normal mice (C) and of mice inoculated via the intra-cardiac route with 1 × 106 mCherry-HBMMC (D). Brain sections were 
stained by immunofluorescence for CCR4 (green). Melanoma macrometastases are red and cell nuclei are blue (DAPI), Magnification: ×63. 
Scale bar = 75 µm (C), Scale bar = 50 µm (D). Arrows indicate CCR4 expressing stromal cells in the brain microenvironment.
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Several sets of molecules including selectins and 
their ligands as well as chemokine receptors and their 
ligands are involved in trans-endothelial migration of 
tumor  cells en route to metastatic sites [17]. We previously 
demonstrated that astrocytes facilitate melanoma 
cell migration [18]. Therefore, we asked whether the 
migration-enhancing effect of astrocytes is mediated, at 
least in part, by CCR4 ligands secreted from these cells. 
The capacity of astrocyte-derived soluble factors 
to chemo-attract CCR4hi and CON cells was assessed by 
utilizing transwell migration assays. Human astrocytes 
(HA) were added to the lower chamber of the transwell 
and melanoma cells (CCR4hi or CON) were added to the 
upper well. Analysis of the results indicated that CCR4hi 
cells migrated more efficiently in response to astrocyte-
secreted soluble factors as compared with control cells 
(Figure 4D–4E). We next asked whether astrocyte-induced 
melanoma cell migration could be mediated by the CCR4 
ligands CCL17 and/or CCL22. Transwell migration 
assays using recombinant CCL17 or CCL22 revealed that 
CCL17, but not CCL22 (data not shown), significantly 
facilitated migration of the CCR4hi cells compared to 
control cells (CON), indicating that expression of CCR4 
facilitates melanoma cell migration (Figure 4F–4G). It 
should be noted that the forced expression of CCR4 in 
melanoma cells (yielding CCR4hi cells) enhanced also the 
spontaneous migration capacity of the melanoma cells 
(Figure 4D–4E).
Neutralizing CCL17 with specific Ab added to 
conditioned medium of the astrocytes, significantly 
inhibited the migration and transendothelial migration of 
brain metastasizing melanoma cells (Figure 4H–4I). These 
results show that the CCL17-CCR4 axis has a functional 
role in astrocyte-mediated melanoma cell migration. Thus, 
the interaction of CCR4, expressed by melanoma cells, 
with its CCL17 ligand in the brain may contributes to 
targeted migration of melanoma cells to the brain.
CCR4 promotes in-vivo growth of cutaneous 
melanoma tumors and brain metastasis
To answer the question if CCR4 plays a functional 
role in the growth of cutaneous melanoma and brain 
metastasis, CCR4hi or control cells were subcutaneously 
(s.c) inoculated into nude mice (5 × 105 cells per mouse). 
Local tumors were measured 3 wks following inoculation 
and the metastatic load in the brain was determined by a 
qRT-PCR based method, developed in our lab, to assess 
the presence of human cells in xenografted nude mice [5]. 
Whereas mice inoculated with control cells developed no 
tumors or very small ones, tumor load in mice inoculated 
with CCR4 over-expressing (CCR4hi) cells was significantly 
higher (Figure 5A). A quantitative evaluation of brain 
metastasis indicated that 50% (3 of 6) of the mice inoculated 
with CCR4hi cells developed micrometastases in the brain, 
while no micrometastases were detected in the brain of mice 
inoculated with control cells (0 of 6) (Figure 5B).
Using flow cytometry-based cell sorting, we selected 
for brain metastasizing melanoma cells (HBMMC from 
the YDFR.CB3 variant), that endogenously express high 
levels of CCR4 (Figure 5C, 5D). The sorted cells, referred 
to here after as CCR4-SORT cells, were s.c inoculated 
into nude mice, as described above. The parental, unsorted 
HBMMC served as control (Control). Local tumors 
and metastatic load in the brain were measured 3 wks 
following inoculation. Mice inoculated with Control 
Figure 2: CCR4 expression during melanoma progression to brain metastasis. (A) Representative IHC staining with 
anti-CCR4 antibody for PRM, LNM and MBM specimens.  Black bars indicate 100 µm. The insets show a magnification of the melanoma 
lesions. Black arrowheads indicate CCR4-positive melanoma cells. Yellow bars indicate 20 µm. (B) Box plot comparing H score for PRM, 
LNM and MBM. *P ≤ 0.05.
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HBMMC developed smaller tumors than mice inoculated 
with CCR4-SORT HBMMC (Figure 5E, 5F). The weight 
of mice inoculated with CCR4-SORT was significantly 
lower than that of mice inoculated with Control cells 
suggesting that the former mice suffered from cachexia 
(Figure 5G). 40% (2 of 5) of the mice inoculated with 
CCR4-SORT cells developed brain micrometastases ,while 
no brain micrometastases were detected in mice inoculated 
with Control cells (Figure 5H). 
Taken together, these results clearly indicate that 
CCR4 is functionally involved in the tumorigenicity of 
melanoma as well as in the formation of brain metastasis.
Antagonizing CCR4 ameliorates the malignancy 
phenotype of melanoma 
To test whether pharmacological inhibition of the 
CCR4 axis will affect brain metastasis, we utilized the 
small molecule CCR4 antagonist AF-399/42016530 [19]. 
This antagonist blocked CCL22- and CCL17-mediated 
migration of human peripheral blood CD4+CD25+ Treg 
and Th2 cells ex-vivo [19] and murine Tregs in-vivo [20].
In the present set of experiments, we tested the effect 
of this CCR4 antagonist on several in-vitro and in-vivo 
malignancy parameters. 
Figure 3: CCR4 ligands are expressed and secreted by human brain stromal cells. (A–B) Chemokine secretion analysis by 
human chemokine array. CCL17 (A) and CCL22 (B) are secreted by human endothelial cells, astrocytes (HA) and microglia (MG). (C–D) 
Chemokine secretion analysis by human chemokine array.  Melanoma cells alter the secretion of CCL17 (C) and CCL22 (D) by microglial 
cells: Microglial cells treated with local melanoma cell-conditioned media (MG+Local), treated with brain metastasizing melanoma cell-
conditioned media (MG+HBMMC), microglial cells alone served as control. (E–F) The bearing of melanoma tumors leads to alterations 
in the expression of CCR4 ligands in the brain. (E) Nude mice were s.c inoculated with 1 × 106 human brain metastasizing melanoma cells 
(YDFR.CB3). Three, five or ten weeks following inoculation (3W, 5W and 10W) brains were removed and analyzed for Ccl17 (E) and 
Ccl22 (F) expression  levels using qRT-PCR . W = weeks. *p < 0.05, **p < 0.005, n = 3.
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We demonstrated above that CCR4 facilitates 
melanoma cell migration towards astrocyte-derived 
soluble factors (Figure 4). Based on these results we 
evaluated the effect of the CCR4 antagonist on the 
migration of brain-metastasizing melanoma cells, 
expressing high levels of CCR4, towards astrocyte 
secreted factors as compared with the migration of local 
cutaneous melanoma cells, expressing very low levels of 
CCR4. Serum free medium with DMSO (the vehicle of 
CCR4 antagonist) served as control. The results confirmed 
that brain-metastasizing melanoma cells migrated better 
towards astrocyte-conditioned medium than local, 
cutaneous melanoma cells (Figure 6A–6B). The CCR4 
antagonist significantly inhibited astrocyte-induced 
migration of brain-metastasizing melanoma cells but did 
not affect the migration of local melanoma cell, further 
supporting a role for CCR4 in facilitating brain metastasis. 
In the next set of experiments, we evaluated 
the effect of CCR4 antagonist on tumorigenicity and 
metastasis formation. Nude mice inoculated s.c with 
CCR4hi cells were treated twice weekly with 1.5 μg 
of CCR4 antagonist, a dose that has been optimized in 
previous experiments [19]. Treatment was initiated 2 wks 
after the inoculation of CCR4hi cells. At this time point, 
some of the mice bear melanoma micrometastases in the 
brain parenchyma [18]. Control mice were treated with 
10% DMSO [19]. Tumor volume was measured on a 
weekly basis (Figure 6C). The results (Figure 6) indicated 
that the CCR4 antagonist did not have a significant 
effect on tumor volume. The antagonist did, however 
influence metastasis formation. Whereas, half of the 
mice (3 of 6) in the control group (DMSO) developed 
brain micrometastases, only one of six mice (17%) in the 
treatment group developed micrometastases (Figure 6D).
The next in-vivo experiments examining the effect 
of triweekly treatments of the CCR4 antagonist on 
tumorigenesis and metastasis formation was performed 
with mice inoculated with HBMMC enriched for high 
endogenous CCR4 expression (CCR4-SORT cells). 
Unsorted cells served as controls. 
The results indicated that the CCR4 antagonist 
exerted a significant effect both on local tumors as well 
as on metastasis (Figure 6E–6H). The tumors in the 
treatment group were significantly smaller than the 
tumors in the control (DMSO) group (Figure 6E–6G). 
Brain micrometastasis formation was also inhibited by 
the antagonist. Whereas 3 out of 5 mice (60%) in the 
control group developed brain micrometastases, only one 
mouse in the treatment group of 5 mice (20%) developed 
micrometastases (Figure 6H). 
Taken together the results of these experiments 
indicated that targeting CCR4 expressed on melanoma 
Figure 4: CCR4 ligands secreted by human stromal brain cells induce melanoma cell migration. (A–B) FACS analysis 
for CCR4 expression  by local melanoma cells infected with empty plasmid (CON- red) (A), or with CCR4 cDNA (CCR4hi-green) (B). (C) 
Viability (XTT-based assay) of control (CON) cells and of CCR4 over-expressing melanoma cells (CCR4hi). (D–I) Migration assays.(D) 
Representative images of migrated CCR4hi and CON cells following 24 h incubation with astrocyte-derived soluble factors (conditioned 
medium - HA CM) as compared to cells that were allowed to migrate towards serum free medium (SFM). (E) Quantification of (D). (F) 
Representative images of  migrated local and brain metastasizing melanoma cells  (HBMMC) 24 h following incubation with 10 ng/
ml recombinant CCL17 (rCCL17). (G) Quantification of (F). (H–I) Neutralizing anti –CCL17 Ab reduce melanoma cell migration and 
transendothelial migration (TEM). (I) Melanoma cells were incubated with HA CM (control) or with HA CM supplemented with 1 µg/ml 
neutralizing Ab to CCL17. Representative images of migration assays are shown. I Quantification of (H). Data shown are mean pixel 
density normalized to control (SFM). Experiments were performed in triplicate and four independent fields/well were quantified. *P < 0.05 
**P < 0.005, n = 3.
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cells ameliorates their malignant phenotype in-vitro and 
in-vivo suggesting that CCR4 antagonists may have a 
therapeutic potential in melanoma.
DISCUSSION
The pioneering work of Muller and colleagues [21], 
indicated that the interactions between chemokine 
receptors expressed by tumor cells and the corresponding 
chemokine ligands expressed in various organs constitute a 
major mechanism for the targeted migration of these tumor 
cells to form site specific metastasis. This mechanism 
was later shown to operate in a variety of tumors using 
different chemokine-mediated pathways [22, 23].
CCR4 is expressed by TH2 and Treg. As such, 
it may serve as target in clinical situations requiring 
suppression of these cells [9, 24, 25]. Blockade of 
CCL22-CCR4 interaction by monoclonal antibodies to 
CCL22 significantly reduced Treg migration to ovarian 
tumors in experimental models [26]. CCR4 is expressed 
by peripheral T-cell lymphoma and T-cell leukemia and 
a humanized Ab directed against CCR4 is used to treat 
these types of cancer [27]. CCR4 is also expressed by non-
lymphoid solid tumors such as breast, lung and colorectal 
cancer as well as by hepatocellular carcinoma. The tumor 
-associated CCR4 may contribute to the metastatic spread 
of these tumor cells [28–33]. Therefore, targeting CCR4 
represents an emerging strategy for cancer therapy [34].
By employing local (cutaneous) and brain-
metastasizing variants generated in nude mice 
xenotransplanted with cells from single human melanoma 
tumors (thereby ensuring a uniform genetic background 
of such variants), we established a molecular signature 
of human brain-metastasizing melanoma cells [5–7]. 
CCR4 was a member of this signature: Its expression 
was higher in cells originating in brain-metastasizing 
Figure 5: CCR4 promotes growth of cutaneous melanoma tumors and of brain metastasis. The following two types of 
CCR4 overexpressing cells and their corresponding controls were s.c inoculated into nude mice: 1. Cells infected with CCR4 cDNA 
(CCR4hi) or control cells (empty plasmid). 2. FACS sorted cells for high CCR4 expression: Control cells (un sorted) or CCR4-sorted cells 
(CCR4-SORT). 12 wks following inoculation, local tumors were excised and brains were removed and analyzed for metastasis formation. 
(A) Tumors of the CCR4hi and Control mouse groups. (B) Brain micrometastasis in the CCR4hi and Control mouse groups (n = 6). (C) 
CCR4 expression in unsorted cells. (D) CCR4 expression in CCR4-sorted cells. Red-negative control, Green-CCR4. (E) Tumors of the 
CCR4-SORT and Control mouse groups. Tumor weight (gr) (F) and mouse weight (gr) (G) of mice injected with unsorted control cells or 
with CCR4-SORT cells. (H) Brain micrometastasis in the CCR4-SORT and Control mouse groups (n = 5). qRT-PCR was used to determine 
the percentage of human melanoma cells in mouse brains.
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Figure 6: CCR4 antagonism ameliorates the malignancy phenotype of melanoma. (A–B) The CCR4 antagonist reduces 
melanoma cell migration. Local and HBMMC were incubated in serum-free medium (SFM), SFM supplemented with migration-
stimulating astrocyte-derived soluble factors (HA CM), SFM + 10 µM CCR4 antagonist, SFM supplemented with HA CM and 10 µM 
CCR4 antagonist. (A) Representative images of migrated local and HBMMC cells following 24 h incubation (B) Quantification of A. 
Data shown are number of migrated cells counted cells in four independent fields/well; **p < 0.005, ***p < 0.0005. (n = 3). (C–D) CCR4 
over-expressing melanoma cells (CCR4hi) were s.c inoculated into nude mice.  Two wks post cell inoculation mice were treated, twice 
a week, with CCR4 antagonist (1.5 μg) or with DMSO (vehicle Control). 12 wks following inoculation local tumors were excised and 
brains were removed and analyzed for metastasis formation. (C) Tumors of antagonist-treated and control mice. (D) Brain micrometastasis 
in antagonist-treated and control mice (n = 6). (E) CCR4-sorted melanoma cells were s.c inoculated into nude mice.  One wk post cell 
inoculation mice were treated, every 2 days, with CCR4 antagonist (1.5 μg) or with DMSO (Control). 12 wks following inoculation local 
tumors were excised and brains were removed and analyzed for metastasis formation. (F) Antagonist-treated and control mice. (G) Tumors 
of antagonist-treated and control mice. (H) Brain micrometastasis in antagonist-treated and control mice (n = 5).
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melanoma variants than in cells of the corresponding 
cutaneous variants [5, 6, 12]. The CCR4 ligands CCL17 
and CCL22 were found to be expressed in brain [6] and 
their expression levels were upregulated in nude mice 
bearing xenografted human melanoma tumors [13]. 
Vemurafenib-resistant melanoma cells expressed higher 
levels of CCR4 than vemurafenib-sensitive cells, which 
are less malignant [13]. Moreover, soluble factors from the 
brain microenvironment upregulated CCR4 expression on 
melanoma cells [12]. 
All these findings prompted us to investigate if 
melanoma-associated CCR4 is functionally involved in 
brain metastasis. The present study shows that indeed 
CCR4 is a determinant of melanoma brain metastasis. 
This conclusion is based on several independent findings 
namely: Using clinical samples we validated the findings 
that CCR4 expression is upregulated in melanoma 
metastasis; ectopically upregulating CCR4 expression 
by melanoma cells increased their local tumorigenicity 
and ability to form brain metastasis; Enriching for CCR4 
expression increased the malignancy phenotype of 
melanoma cell populations; treating melanoma-bearing 
mice with a small molecule CCR4 antagonist significantly 
reduced local tumourigenicity and metastasis formation. 
Chemo attraction of CCR4-expressing melanoma 
cells towards CCR4 ligands in the brain seems to be a 
major mechanism by which this receptor exerts its pro-
metastatic activity. We found that the expression of the 
CCR4 ligand Ccl17 is upregulated in the brain of mice 
bearing local melanoma tumors but no detectable brain 
metastasis. This suggests that cues derived from the local 
cutaneous melanoma may be capable of regulating, at 
distance, the expression of this chemokine ligand. The 
increased levels of CCL17 in the brain could chemo-
attract tumor cells expressing the corresponding CCR4 
receptor to the brain.
In addition to the involvement of the CCL17-CCR4 
axis in chemo-attracting melanoma cells to the brain, 
other pro-metastatic mechanisms of this axis may also be 
operative. For example, CCR4- expressing Tregs recruited 
to tumor sites may antagonize the anti- tumor activities of 
cytotoxic T cells thereby contributing to tumor growth. 
This mechanism is however not operative in xenograft 
models (such as the one used in this study) utilizing 
immune deficient mice. Another mechanism is the 
proliferation-boosting activity of CCR4. As demonstrated 
above and previously by others [35] the interaction 
between CCR4 expressed by tumor cells and its ligands 
promotes the proliferation of the tumor cells. 
The results described above and elsewhere [28, 33] 
indicated that of the two CCR4 ligands, CCL17 is the 
chemokine involved in the pro-malignant functions of 
CCR4. CCL17 was sufficient to enhance melanoma cell 
invasiveness, and neutralizing this ligand in astrocyte-
conditioned medium attenuated the astrocyte-mediated 
migration of melanoma cells.
CCL22 is apparently not involved in the migratory 
function of melanoma cells. Indeed a suppression of 
CCL22 and a concomitant increase of CCL17 levels in 
the cerebrospinal fluid characterize patients with highly 
aggressive MBM [36]. The underlying reason for the 
differential effect of these two chemokines on melanoma 
progression is not clear. Possible differences in the 
expression pattern of CCR4 on tumor cells vs lymphocytes 
might be one of the reasons as CCL22 is reported to have 
higher affinity for CCR4-expressing lymphocytes [37].
Based on the results of the present study we suggest 
that CCR4 could serve as a target for the therapy of 
melanoma. Clinical trials with the humanized anti-CCR4 




Human melanoma: The YDFR cell line was 
described previously [38]. The production of the cutaneous 
human melanoma variant (YDFR.C) and of the MBM 
variant (YDFR.CB3) were described previously [5], [6]. 
The YDFR.CB4 variant was generated as follows: 5 × 105 
YDFR.CB3 cells were inoculated into the left ventricle of 
the heart. Cells that metastasized to the brain were isolated 
and grown in culture to generate the fourth cycle of brain 
metastatic variants (YDFR.CB4). We also developed a 
local and human MBM variant system from the human 
MBM derived cell lines UCLA-SO-M12 and UCLA-
SO-M16, as was described previously for the YDFR 
model [5, 6]. In this study, we used the metastatic variants: 
M12.CB2, M12.CB3 and M16.CB2 (CB2 and CB3 refer 
to number of cycles of re-inoculation into the left ventricle 
of the heart as previously described) [5].
mCherry YDFR.CB3 cells were infected to stably 
express mCherry (pQCXI–mCherry retroviral vector) as 
described previously [18] (Clontech Laboratories, Inc., 
USA).
CCR4hi YDFR.C - YDFR.C cells were infected to 
over-express CCR4 (pQCXIP–mCherry retroviral vector), 
(CN:631516, Clontech Laboratories, Inc., USA).
Human astrocytes (HA) this cell line was purchased 
from ScienCell Research Laboratories, USA and 
maintained as described previously [18].
Human brain endothelial cells (hCMECs/D3 cells) 
were kindly provided by Clara Nahmias and Pierre-Olivier 
Couraud (Department of Cell Biology, Institute Cochin, 
Paris, France). These cells were used between passages 27 
and 35. These cells were maintained in monolayer cultures 
as previously described [6, 39].
Immortalized Human Microglia - SV40, MG, cell 
line was purchased from ABM. The cells were maintained 
in monolayer cultures in Prigrow III medium (ABM, 
Milton, Canada). 
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Cells were cultured in humidified air with 6.5% 
CO2 at 37°C. The cultures were routinely tested and found 
to be free of mycoplasma.
Animals
Male athymic nude-BALB/c mice were purchased 
from Harlan Laboratories Limited (Jerusalem, Israel). 
The mice were housed, maintained and used as described 
previously (5, 6). All experiments involving animals were 
approved by the TAU Institutional Animal Care and Use 
Committee.
Orthotopic and intracardiac inoculation of 
tumor cells
Subcutaneous and Intracardiac (IC) inoculation were 
performed as described previously [5].
Antibodies
Monoclonal anti-human CCR4 (R&D Systems, 
Minneapolis, MA, USA) was used for flow cytometry and 
immunofluorescence. FITC-CCR4 anti-mouse, (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) 
was used according to manufacturer instructions.
Flow cytometry 
Human melanoma cells were cultured and FACS 
analyzed as previously described [6].
Immunohistochemistry (IHC) and 
immunofluorescence staining
Cutaneous melanoma patients were included in 
the study at John Wayne Cancer Institute under the 
MORD-RTPCR-0995 protocol approved by the Western 
Institutional Review Board (WIRB Protocol #20072107). 
Informed consent was obtained from all subjects and the 
experiments performed according to the principles set 
out in the WMA Declaration of Helsinki and the NIH 
Belmont Report. Tissue specimens were de-identified and 
coded according to HIPAA recommendations to ensure the 
confidentiality of the patients.
Details are given in Supplementary materials and 
methods (See supplementary material).
In-vivo tumorigenicity assay
To test the tumorigenic properties of derived cell lines, 
1 × 106 cells in 100 μl of 5% FCS RPMI-1640 medium were 
s.c injected into nude mice. Local SC tumors were measured 
once a week using a caliper as previously described [40]. 
Tumor volume was evaluated by the ellipsoid volume 
calculation formula 0.5 × (length × width2) [40]. 
RNA preparation and reverse transcription 
polymerase chain reaction 
Quantitative real-time polymerase chain reaction 
(RT-qPCR) was performed as we previously described [6]. 
Details are given in Supplementary materials and methods 
(See supplementary material).
Chemokine secretion analysis
Human brain endothelial cells, Microglia and HAs 
were incubated in starvation medium for 24 h. Then cells 
were lysed and 100ng were analyzed for the relative 
expression of 36 chemokines (Proteome Profiler Human 
Chemokine Array Kit Panel A, R&D Systems, Canada). 
3D matrigel culture
MBM were cultured in matrigel to form 3D culture as 
previously described [41]. Microglia conditioned-medium 
(MG CM) was prepared as previously described [18].
Migration and transendothelial migration
Migration and transendothelial migration were 
performed as previously described [18].
For CCR4 antagonist-attenuated migration assays, 
10 ng/ml of CCR4 antagonist (AF-399/42018025) [19, 20] 
were added to the upper chamber of transwell plates for 
24 h stimulation.
CCL17-induced migration and invasion assays
10 ng/ml recombinant CCL17 (R&D Systems, 
Canada) were added to the lower chambers of Transwell 
plates for 24 h of stimulation. For CCL17-blocking 
studies, 1 µg/ml anti-human CCL17 neutralizing Ab (R&D 
Systems, Canada) was added to astrocyte CM for 24 h.
Isolation and characterization of CCR4+ sorted 
melanoma cells
Details are given in Supplementary materials and 
methods (see supplementary material).
Treating mice with CCR4 antagonist
Mice were orthotopically inoculated with human 
HBMMC expressing high endogenous levels of CCR4 
or (1 × 106) with CCR4hi cells (0.5 × 106). Two wks 
following tumor inoculation, mice were treated with the 
CCR4 antagonist (SP46 - AF-399/42018025) [20], (in 
10% DMSO) or with DMSO alone (control). 1.5 μg/50 μl 
of antagonist were injected intraperitoneally (IP) twice a 
week for 12 wks. 
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Statistical analysis
Data were analyzed using Student’s t-test and 
considered significant at P-values ≤ 0.05. Bar graphs 
represent mean and standard deviation (SD) across multiple 
independent experimental repeats, unless otherwise stated.
Statistical differences on the H-score values were 
analyzed by using the Kruskal-Wallis test among the 
groups. Additionally, the Steel-Dwass method was used 
to further compare between groups were considered 
statistically significant. The statistical analyses were 
performed with EZR (Saitama Medical Center, Jichi 
Medical University, Saitama, Japan, version 1.32), which 
is a graphical user interface for R (The R Foundation for 
Statistical Computing, Vienna, Austria).
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